Advertisement

Efficacy of Levosimendan in the Treatment of Patients With Severe Septic Cardiomyopathy

Published:November 05, 2022DOI:https://doi.org/10.1053/j.jvca.2022.10.032

      Objective

      This study was designed to compare the effects of levosimendan and dobutamine on hemodynamics and clinical efficacy in patients with severe septic cardiomyopathy (left ventricular ejection fraction [LVEF] ≤35%).

      Design

      A prospective, single-blind, randomized controlled study.

      Setting

      In Baoding, China.

      Participants

      Thirty patients with severe septic cardiomyopathy treated in the authors’ hospital's Department of Critical Medicine from September 2018 to September 2021 were enrolled in this study.

      Interventions

      These patients were divided randomly into the levosimendan group and dobutamine group. The LVEF, cardiac index (CI), stroke volume index (SVI), systemic vascular resistance index, heart rate, norepinephrine dose, and lactate at the time of enrollment and the 24th hour were compared, along with myocardial injury markers on the third day, C-reactive protein, mechanical ventilation time, length of intensive care unit (ICU) stay, cost, and 28-day mortality. The primary outcome was 28-day mortality.

      Measurements and Main Results

      At the 24th hour after treatment, CI, LVEF, SVI, and fluid volume were found to be higher in the levosimendan group than in the dobutamine group, whereas the dose of norepinephrine was lower in the former rather than the latter group. On the third day of treatment, cardiac troponin I in the levosimendan group was lower than that in the dobutamine group. Although the differences in 28-day mortality, ICU stay, and ICU treatment cost between the groups were not statistically significant, the ventilator application time of the levosimendan group was significantly shorter than that of the dobutamine group.

      Conclusions

      Compared with dobutamine, levosimendan was more effective at improving cardiac function, reducing myocardial injury, and reducing mechanical ventilation time in patients with severe septic cardiomyopathy.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Andrea M
        • Stefna DC
        • Jean-Louis T
        • et al.
        Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression.
        Intensive Care Med. 2005; 31: 638-644
        • Silvetti S
        • Nieminen MS.
        Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
        Int J Cardiol. 2016; 202: 138-143
        • Meng JB
        • Hu MH
        • Lai ZZ
        • et al.
        Levosimendan versus dobutamine in myocardial injury patients with septic shock: A randomized controlled trial.
        Med Sci Monit. 2016; 22: 1486-1896
        • Fei Y
        • Li Na Z
        • Yi S
        • et al.
        Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy: Mechanism and clinical application.
        J Int Med Res. 2019; 47: 1817-1828
        • Gordon AC
        • Perkins GD
        • Singer M
        • et al.
        Levosimendan for the prevention of acute organ dysfunction in sepsis.
        N Engl J Med. 2016; 375: 1638-1648
        • Antcliffe DB
        • Santhakumaran S
        • Orme RML
        • et al.
        Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: A subgroup analysis of the LeoPARDS randomised trial.
        Intensive Care Med. 2019; 45: 1392-1400
        • Jin-Joo P
        • Alexandre M
        • In-Chang H
        • et al.
        Phenotyping heart failure according to the longitudinal ejection fraction change: Myocardial strain, predictors, and outcomes.
        J Am Heart Assoc. 2020; 9e015009
        • Jih-Kai Y
        • Yuan-Chuan H
        • Cian-Ruei J
        • et al.
        Comparison of baseline versus posttreatment left ventricular ejection fraction in patients with acute decompensated heart failure for predicting cardiovascular outcome: Implications from single-center systolic heart failure cohort.
        PLoS One. 2016; 11e0145514
        • Cunha-Goncalves D
        • Perez-de-Sa V
        • Larsson A
        • et al.
        Inotropic support during experimental endotoxemic shock: Part II. A comparison of levosimendan with dobutamine.
        Anesth Analg. 2009; 109: 1576-1583
        • Rincón VJA
        • Martínez MJ
        • Monteón BI
        • et al.
        Levosimendan treatment of myocardial depression in sepsis: A case series and review of the literature.
        Medicana Interna De Mexico. 2010; 26: 324-336
        • Zied H
        • Bilel M
        • Walid S
        • et al.
        Effects of levosimendan on cellular metabolic alterations in patients with septic shock: A randomized controlled pilot study.
        Shock. 2017; 48: 307-312
        • Julia H
        • Klaudija B
        • Cristina B
        • et al.
        Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: A prospective observational study.
        Crit Care. 2011; 15: R166
        • Hsieh-Chou H
        • Hsin-Jung T
        • Chao-Chun W
        • et al.
        Levosimendan mitigates coagulopathy and organ dysfunction in rats with endotoxemia.
        J Chin Med Assoc. 2017; 80: 432-441
        • Cheng-Ming T
        • Kai-Yi Shiu-Jen C
        • et al.
        Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: Studies in a rat model.
        Crit Care. 2014; 18: 652-664
        • Alessandro B
        • Umberto B
        • Giuseppe BZ
        • et al.
        The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials.
        J Crit Care. 2017; 37: 91-98
        • Alberto Z
        • Alessandro P
        • Fabrizio M
        • et al.
        Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials.
        J Crit Care. 2015; 30: 908-913
        • William J
        • Damien F
        • Laureline F
        • et al.
        Levosimendan plus dobutamine in acute decompensated heart failure refractory to dobutamine.
        J Clin Med. 2020; 9: 3605